Exagen Inc. announced that AVISE® tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to enhanced care to participating members. The agreement includes Exagen's AVISE® Lupus and AVISE® CTD tests making AVISE diagnostic testing available as an in-network benefit.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | +2.17% | -1.32% | -29.15% |
Mar. 18 | Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, vs. Street Est of $11.6M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.15% | 23.79M | |
-15.26% | 85.42B | |
+16.05% | 84.38B | |
+10.92% | 29.39B | |
-13.07% | 17.49B | |
-3.17% | 16.44B | |
-2.36% | 15.28B | |
-0.45% | 12.22B | |
-31.23% | 11.98B | |
-2.51% | 11.71B |
- Stock Market
- Equities
- XGN Stock
- News Exagen Inc.
- Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems